162 related articles for article (PubMed ID: 38046900)
1. Randomized trial of intravenous versus bidirectional chemotherapy after cytoreductive surgery for malignant peritoneal mesothelioma.
Sugarbaker PH
Int J Surg Protoc; 2023 Dec; 27(3):108-117. PubMed ID: 38046900
[TBL] [Abstract][Full Text] [Related]
2. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival.
Sugarbaker PH; Chang D
Eur J Surg Oncol; 2017 Jul; 43(7):1228-1235. PubMed ID: 28189456
[TBL] [Abstract][Full Text] [Related]
3. Update on the management of malignant peritoneal mesothelioma.
Sugarbaker PH
Transl Lung Cancer Res; 2018 Oct; 7(5):599-608. PubMed ID: 30450299
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
de Boer NL; van Kooten JP; Burger JWA; Verhoef C; Aerts JGJV; Madsen EVE
BMJ Open; 2019 May; 9(5):e026779. PubMed ID: 31092657
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I/II dose escalation and safety study-INTERACT MESO.
van Kooten JP; Dietz MV; Guchelaar NAD; Brandt-Kerkhof ARM; Koolen SLW; Burger JWA; Mathijssen RHJ; Verhoef C; Aerts JGJV; Madsen EVE
BMJ Open; 2022 Jun; 12(6):e062907. PubMed ID: 35732399
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
7. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: patient selection and special considerations.
Enomoto LM; Shen P; Levine EA; Votanopoulos KI
Cancer Manag Res; 2019; 11():4231-4241. PubMed ID: 31190990
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal mesothelioma: a phase II clinical trial.
Dietz MV; Quintelier KLA; van Kooten JP; de Boer NL; Vink M; Brandt-Kerkhof ARM; Verhoef C; Saeys Y; Aerts JGJV; Willemsen M; Van Gassen S; Madsen EVE
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37536940
[TBL] [Abstract][Full Text] [Related]
9. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin in pediatric patients with peritoneal mesothelioma: a single institution experience and long term follow up.
Malekzadeh P; Good M; Hughes MS
Int J Hyperthermia; 2021; 38(1):326-331. PubMed ID: 34139940
[TBL] [Abstract][Full Text] [Related]
10. Bidirectional chemotherapy allowing surgery and HIPEC for malignant peritoneal mesothelioma.
Noiret B; Eveno C
Pleura Peritoneum; 2019 Jun; 4(2):20190011. PubMed ID: 31417959
[TBL] [Abstract][Full Text] [Related]
11. Clinical Trial Protocol for HyNOVA: Hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial OVArian, fallopian tube and primary peritoneal cancer (ANZGOG1901/2020).
Farrell R; Burling M; Lee YC; Pather S; Robledo K; Mercieca-Bebber R; Stockler M;
J Gynecol Oncol; 2022 Jan; 33(1):e1. PubMed ID: 34783204
[TBL] [Abstract][Full Text] [Related]
12. Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy.
Le Roy F; Gelli M; Hollebecque A; Honoré C; Boige V; Dartigues P; Benhaim L; Malka D; Ducreux M; Elias D; Goéré D
Ann Surg Oncol; 2017 Nov; 24(12):3640-3646. PubMed ID: 28849389
[TBL] [Abstract][Full Text] [Related]
13. Ten-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Acs M; Gerken M; Gajic I; Mayr M; Zustin J; Piso P
Langenbecks Arch Surg; 2022 Nov; 407(7):3057-3067. PubMed ID: 35732846
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant bidirectional chemotherapy with intraperitoneal pemetrexed combined with intravenous Cisplatin for diffuse malignant peritoneal mesothelioma.
Bijelic L; Stuart OA; Sugarbaker P
Gastroenterol Res Pract; 2012; 2012():890450. PubMed ID: 22927839
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.
Quénet F; Elias D; Roca L; Goéré D; Ghouti L; Pocard M; Facy O; Arvieux C; Lorimier G; Pezet D; Marchal F; Loi V; Meeus P; Juzyna B; de Forges H; Paineau J; Glehen O;
Lancet Oncol; 2021 Feb; 22(2):256-266. PubMed ID: 33476595
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma: Canadian practices and outcomes.
Deban M; Taqi K; Knapp GC; Soucisse M; Curry M; Sidéris L; Dubé P; Khaldi MA; Jedrzejko N; Porter G; Giacomantonio C; Hamilton T; MacNeill A; Mack L; Bouchard-Fortier A
J Surg Oncol; 2023 Sep; 128(4):595-603. PubMed ID: 37249154
[TBL] [Abstract][Full Text] [Related]
17. National Practice Patterns in Malignant Peritoneal Mesothelioma: Updates in Management and Survival.
Calthorpe L; Romero-Hernandez F; Casey M; Nunez M; Conroy PC; Hirose K; Kim A; Kirkwood K; Maker AV; Corvera C; Nakakura E; Alseidi A; Adam MA
Ann Surg Oncol; 2023 Aug; 30(8):5119-5129. PubMed ID: 37140748
[TBL] [Abstract][Full Text] [Related]
18. A 51-Year-Old Woman with Advanced Peritoneal Mesothelioma and Stage 3b Chronic Kidney Disease Treated with Cytoreductive Surgery and Bidirectional Intraperitoneal Cisplatin and Ifosfamide Chemotherapy: A Case Report.
Alaswad M; ElKordy F; Jaamour H; Al Otry A; Azzam AZ; Amin TM; Khoja HA
Am J Case Rep; 2023 Dec; 24():e941726. PubMed ID: 38093612
[TBL] [Abstract][Full Text] [Related]
19. [Meta analysis of whether cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy can improve survival in patients with colorectal cancer peritoneal metastasis].
Liu D; Wang H; Yuan ZX; Chen WW; Wu ZJ; Liu XX; Luo J; Chu LL; Li Y; Cai J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):256-263. PubMed ID: 34645170
[No Abstract] [Full Text] [Related]
20. Value of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy to treat malignant peritoneal mesothelioma.
Wang T; Li H; Ye B; Zhang D
Am J Transl Res; 2021; 13(9):10712-10720. PubMed ID: 34650746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]